

Neurological Aspects of HIV/Human T Lymphotropic Virus Coinfection

Marcus Tullius Silva, Otávio de Melo Espíndola, Ana Cláudia C. Bezerra Leite and Abelardo Araújo

Laboratory for Clinical Research in Neuroinfections and Laboratory for Clinical Research in Viral Pathogenesis, Instituto de Pesquisa Clínica Evandro Chagas (IPEC), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil

Abstract

Human T lymphotropic virus type 1 is associated with some neurologic diseases, mainly human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Human T lymphotropic virus type 2 has also been associated with similar cases of human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis, but evidences for a definitive relationship are less clear. On the other hand, neurologic manifestations of HIV infection are quite common, affecting more than one third of patients in HIV clinics. Seroepidemiologic studies show that HIV-infected individuals are at an increased risk for human T lymphotropic virus infection and vice versa in comparison with the general population. Furthermore, HIV/human T lymphotropic virus coinfection has been associated with distinctive immunophenotypes and an increased risk for development of neurodegenerative conditions. Thus, studies on HIV/human T lymphotropic virus coinfection have a practice clinical importance. In this review, we aim to discuss clinical and laboratorial data focusing on neurologic diseases in HIV/human T lymphotropic virus coinfection. (AIDS Rev. 2009;11:71-8)

Corresponding author: Abelardo Araújo, abelardoaraujo@terra.com.br

Key words

HTLV-1. HAM/TSP. HTLV-2. ATL. HIV. Coinfection.

Introduction

Undoubtedly, the efforts to isolate both human T lymphotropic virus type 1 (HTLV-1)¹ and type 2 (HTLV-2)² enabled the identification of HIV. This fact eventually overshadowed the significance of the discovery of HTLV. Infection with HTLV-1 has a considerable social and economic impact: the infection is endemic in limited-resource areas such as Africa, the Caribbean, and South America. Human T lymphotropic virus type 1-associated myelopathy/tropical spastic

paraparesis (HAM/TSP)³ is a disabling condition, mostly diagnosed during the most economically productive years of life and is the main neurologic disease caused by this retrovirus. Additionally, other neurologic conditions have also been associated with HTLV-1 infection, which strengthens the concept of the high potential of HTLV-1 to affect the nervous system⁴. Interestingly, in patients with HTLV-1-associated neurologic conditions, the HTLV-1 proviral load is higher than in asymptomatic carriers⁵. This is remarkable because a high proviral load is associated with an increased risk for diseases in HTLV-1-infected individuals⁶.

Since the beginning of the HIV epidemic, neurologic disorders have been reported as very frequent and debilitating among AIDS patients⁷. For example, the nervous system is affected in 26-94% of HIV-infected individuals in Brazil⁸, and the same is observed in other countries. Considering that (i) HIV-infected patients are at an increased risk for HTLV infection and *vice versa*, (ii) HIV/HTLV coinfection seems to

Correspondence to:

Abelardo Araújo
Instituto de Pesquisa Clínica Evandro Chagas-FIOCRUZ
Avenida Brasil, 4365
Rio de Janeiro, Brazil
E-mail: abelardoaraujo@terra.com.br

increase the risk for neurologic diseases, and (iii) the effects of HAART on HIV/HTLV coinfection are not yet completely understood, reviews about HIV/HTLV coinfection are of utmost importance. Therefore, in the present review we aim to discuss clinical and laboratory data, focusing on neurologic diseases in HIV/HTLV coinfection.

Cellular and molecular biology of coinfection: *In vitro* and *in vivo* HIV/human T lymphotropic virus interactions

Both HIV and HTLV share similar genomic organization and encode structural and enzymatic proteins typical to all retroviruses⁹. In addition, their genomes encode accessory proteins that seem to play an important role in viral pathogenesis, such as Tax and Rex in HTLV infection¹⁰ and Tat and Rev in HIV infection¹¹. However, the replication strategies used by HIV and HTLV are quite different, which results in distinct outcomes. High levels of virus particles in plasma are observed in HIV infection due to active replication. On the other hand, HTLV-1 is characterized by a poor ability to infect permissive cells as cell-free virions, the chronic infection being maintained mainly by provirus-carrying cell proliferation¹².

The frequency of HTLV-1/2 infection is unquestionably higher among HIV-infected individuals than in the general population. Furthermore, HIV/HTLV coinfection seems to interfere with the course of the diseases associated with both viruses. *In vitro*^{13,14} and *in vivo*¹⁵ evidences indicate that HIV-1 infection is associated with upregulation of HTLV-1/2 expression and a higher risk for diseases. Superinfection of HTLV-1-transformed cell lines with HIV-1 results in an increased HTLV-1 protein expression¹⁶. Indeed, this enhancement was observed only after infection with active HIV-1 virus, but not following exposure to inactivated viral particles or transfection with the HIV-1 *tat* gene. However, the HIV-1 Rev protein was found to enhance HTLV-1 gene expression, acting through the 5'-RU5 portion of the HTLV-1 genome¹⁴. In addition, peripheral blood mononuclear cells (PBMC) from HIV-1/HTLV-1-coinfected individuals proliferate *in vitro* at a higher rate than HIV-monoinfected cells. This is similar to the spontaneous proliferation observed with HTLV-1-infected PBMC¹⁷.

Recently, it has been shown that intercellular contacts drastically enhance HIV transmission and replication

compared to what is observed with free virus infection¹⁸. This finding indicates that cell-to-cell transfer is the predominant mode of HIV spread. The HIV cell-to-cell transfer relies on a rapid recruitment of the cellular interface of CD4, CXCR4, talin, and lymphocyte function-associated antigen 1 on the target cell and of Env and Gag proteins on the HIV-infected effector cell^{19,20}. This explains the highly efficient HIV replication in lymphoid organs²¹, where high amounts of CD4⁺ T-cell and slow cell movement would facilitate cellular cross talk and viral transmission. As for HIV-1, lymphoid organs are believed to be a major *in vivo* reservoir for HTLV-1, followed by circulating PBMC^{22,23}. Indeed, HTLV-1 has also been shown to spread through an intracellular reorganization of the viral components near the cell-cell junction. This has been termed "virologic synapse"^{24,25}.

Sun, et al. demonstrated that HIV-1-infected cells can fuse with both HTLV-1-expressing cells and latently HTLV-1-infected cells, and the resulting syncytia could function as a "tunnel" by which the Tax protein would diffuse, leading to a more potent induction of HTLV-1 proteins and virions in cells harboring latent HTLV-1 provirus²⁶. This HIV-1-dependent transfer of HTLV-1 Tax protein might explain, at least partially, why coinfection with HIV-1 allows HTLV-1 to overcome the strong and chronically activated T-cell response, which could result in the onset of HAM/TSP in a higher proportion of coinfecting individuals.

On the other hand, HTLV-2 downregulates HIV-1 replication in interleukin 2 (IL-2)-stimulated primary PBMC of coinfecting individuals through the expression of macrophage inflammatory protein (MIP) 1 α ²⁷. The MIP-1 α and other CC-chemokines, such as RANTES and MIP-1 β , bind to CCR5, a cell surface coreceptor for macrophage-tropic (M-tropic) HIV-1 strains, which is dominant during early AIDS and clinically latent HIV infection²⁸. In addition, CXCR4 is the coreceptor of the more cytopathic T-cell-tropic (T-tropic) HIV strains²⁹ that emerge in later stages of disease³⁰. The acquisition of CXCR4 usage as coreceptor corresponds to the switch from M-tropic to T-tropic phenotype, to the loss of sensitivity to the suppressive effects of CC-chemokines, and to a significant decrease in CD4⁺ T-cell counts^{30,31}. Besides, HTLV-1-specific CD8⁺ cytotoxic T-lymphocytes derived from patients with HAM/TSP are an important source of MIP-1 α and MIP-1 β ³², suggesting that HTLV-1 and -2 may influence HIV replication via chemokine release. Notably, MIP-1 α alone seems to account for most of the anti-HIV activity, unlike RANTES and MIP-1 β ²⁷. Moriuchi, et al. also observed

this same interference using supernatants from HTLV-1-infected cell cultures. In this experiment, replication of M-tropic HIV-1 was inhibited, but replication of T-tropic was enhanced³³. Altogether, these findings suggest that HTLV-1 or -2 coinfection in HIV-infected individuals may facilitate transition from an M-tropic to a T-tropic HIV phenotype, which is indicative of progression to an advanced stage of HIV disease. Furthermore, coinfection with T-tropic HIV-1 and HTLV-1 significantly enhanced HIV-1 replication, whereas coinfection with M-tropic HIV-1 enhances HTLV-1 expression^{16,34,35}.

In vivo data show that HIV/HTLV-2-coinfected patients present lower levels of T-cell activation, which reflects the lower rate of HIV replication and correlates with the lower HIV RNA load in plasma compared to HIV-monoinfected patients³⁶. This is in agreement with the slower rates in the decrease of CD4⁺ T-cell counts in HIV/HTLV-1/2-coinfected patients, resulting, on average, in higher CD4⁺ T-cell counts^{37,38}. Although *in vitro* and *in vivo* findings are conflicting at first sight, one should consider the stage of HIV disease. Therefore, whereas HTLV-1/2 may accelerate the progression of HIV disease^{27,33}, the immunomodulatory effect of HTLV-1/2 Tax protein would be a positive stimulus for expansion of T-cells at late stages by increasing the synthesis of IL-2 and interferon gamma (IFN- γ) by HTLV-infected cells³⁹. Although higher CD4⁺ T-cell counts in coinfecting subjects could potentially delay the progression to AIDS, an increased frequency of clinical complications, such as thrombocytopenia and respiratory and urinary tract infections, is observed. Therefore, it is possible that CD4⁺ T-cell function presents qualitative defects in coinfecting subjects, which may render this parameter less useful in the clinical setting.

As discussed below, HIV/HTLV coinfection is associated with a higher risk for neurologic diseases. HAM/TSP is a slowly progressive neurodegenerative disease characterized by perivascular cuffing of mononuclear cells accompanied by parenchymal lymphocytic infiltration. *In vitro* assays showed that endothelial cells can be productively infected by HTLV-1 and expression of the tight-junction proteins in these cells is altered, which facilitates lymphocyte traffic and blood-brain barrier (BBB) breakdown⁴⁰. *In situ* hybridization also revealed the presence of HTLV-1 RNA in spinal cord and cerebellar sections, and phenotypic analysis demonstrated that at least some of the infected cells were astrocytes⁴¹. Mor-Vaknin, et al. also showed that BBB breakdown would occur, at

least partially, by syncytium formation between the HTLV-1-infected T-cells and astrocytes⁴². These cells usually respond to trauma, stroke, or neurodegeneration by undergoing cellular hypertrophy. However, it has been demonstrated that, as a consequence of T-cell attack, infected astrocytes undergo polarization, extending a major protrusion towards the immunological synapse formed with effector T-cells, and withdrawing most of their multipolar finer processes⁴³. On the other hand, microglia cells are the main reservoir for HIV-1 in the central nervous system, and multinucleated giant cells, which result from the fusion of HIV-1-infected microglia and brain macrophages, are the hallmark of HIV dementia^{44,45}. Therefore, cells of the monocyte-macrophage lineage are of particular importance in this process due to their ability to cross the BBB and spread HIV-1 infection into the central nervous system (CNS)⁴⁶. Altogether, these events could contribute to BBB breakdown. Levin, et al. presented the case of a patient with both HAM/TSP and HIV-associated dementia⁴⁷. Both viruses were detected in the CNS, but HTLV-1 was localized in astrocytes and HIV in the macrophage/microglia, with no coinfection of a single cell phenotype. This suggests that mechanisms other than coinfection of the same CNS cell may play a role in the development of neurologic disease in HIV/HTLV-coinfected patients. Therefore, BBB breakdown related to HIV and/or HTLV infection could accelerate the emergence of neurodegenerative conditions associated with either virus during coinfection.

HIV/human T lymphotropic virus coinfection and human T lymphotropic virus 1/2 proviral load

Although *in vitro* data suggest that HIV and HTLV could reciprocally enhance their expression, it has been shown that HIV-1 infection does not alter HTLV-1⁴⁸ or HTLV-2⁴⁹ proviral loads in dually infected individuals in comparison to HTLV-1 or -2 monoinfected subjects. *In vivo* data do not rule out the *in vitro*-based hypothesis that HIV-1 coinfection would increase the HTLV-1 proviral burden in the PBMC. However, depletion of the CD4⁺ T-cell subset, the main target of HTLV-1, could be counterbalanced by an upregulation of HTLV-1 replication⁴⁸. Data from HIV/HTLV-2-coinfected subjects under HAART confirmed this event. A transient increase was observed in the HTLV-2 proviral load concomitant to a decrease in HIV-1 viremia. This

would reflect the rapid blocking of HIV-1 replication in response to therapy, causing an increase in the number of circulating T lymphocytes carrying the HTLV-2 proviral DNA^{50,51}.

An increased HTLV-2 proviral load following HAART may predispose HIV-coinfected patients to HTLV-2-related diseases. This may include conditions such as myelopathy⁵², cutaneous lymphoma⁵³, or peripheral neuropathy⁵⁴⁻⁵⁶. Since HTLV-associated diseases usually have a long incubation period, it is probable that the prolonged lifespan of HIV-infected individuals after HAART will allow the observation of more cases of HAM/TSP in the course of HIV/HTLV-1 coinfection.

Clinical outcomes

Since HIV and HTLV affect both the peripheral and the central nervous system, there is a reasonable concern about an increased risk for neurologic diseases in coinfecting individuals, mainly as a result of upregulated HTLV-1 expression during HIV/HTLV coinfection (see above). Double infection with HIV increases HTLV-1 antigen production, suggesting an upregulation of HTLV-1 replication by HIV^{16,34,35}. This *in vitro* observation could explain the increased risk of HAM/TSP during HIV/HTLV-1 coinfection. Levels of HTLV *tax* and *rex* mRNA in PBMC in HIV/HTLV-coinfected patients are higher than in HTLV-monoinfected individuals¹⁵.

Myelopathy

The most common neurologic manifestation of HTLV-1⁴ is HAM/TSP. This disorder manifests clinically by a slow, progressive spastic paraparesis, neurogenic bladder disturbances, and less evident sensory signs. Development of neurologic disability typically occurs during the first or second year of the disease, indicating a possible initial inflammatory phase followed by a more protracted degenerative stage⁵⁷. An important factor that seems to determine the risk for HAM/TSP and its progression is the HTLV-1 proviral load. Patients with high proviral loads are at increased risk for both HAM/TSP development and faster progression of the disability than those with low proviral loads, possibly indicating an increased proliferation or migration of HTLV-1-infected lymphocytes to the CNS⁵⁸. Recently, we have demonstrated that not only HAM/

TSP patients have higher proviral load than asymptomatic carriers; HTLV-1-infected patients with other associated neurologic disturbances can also exhibit a high proviral load. This strengthens the role of a high HTLV-1 proviral load in the pathogenesis of neurologic diseases⁵.

Approximately 2% of HTLV-1-infected individuals will develop HAM/TSP during the course of infection. Also, HTLV-2 has been associated with similar cases of HAM/TSP, although evidences for a definitive relationship are less clear⁵⁹. On the other hand, HIV infection is classically associated with vacuolar myelopathy, a disease clinically similar but histopathologically distinct to HAM/TSP. Around 10% of AIDS patients used to be affected by vacuolar myelopathy in the pre-HAART era⁶⁰, but nowadays this is rarely diagnosed. However, HIV-infected patients are not free from developing myelopathy, considering that HIV-infected patients are at an increased risk for HTLV-infection and that both viruses seem to interact synergistically in terms of the development of neurologic diseases. Thus, it is not surprising that HIV/HTLV-coinfected patients have a higher probability to develop myelopathy, even in the HAART era.

Berger, et al. were the first to assume that HIV-infection might increase the susceptibility for the development of myelopathy in HIV/HTLV-coinfected patients. In a serological survey for HTLV infection in a cohort of 242 HIV-infected patients, they identified two subjects coinfecting by HTLV-1 and two coinfecting by HTLV-2. All coinfecting patients except one (HIV/HTLV-2) had a myelopathy clinically similar to HAM/TSP. Similar results were described in a Brazilian cohort of HIV/HTLV-1-coinfected patients⁶¹. Harrison, et al. reported that the frequency of myelopathy was higher in coinfecting than in HIV-monoinfected patients (11/15 HIV/HTLV-coinfected versus 10/62 HIV-monoinfected individuals; OR: 14; $p < 0.00004$). More recently, Beilke, et al. described four cases of myelopathy among 41 HIV/HTLV-1-coinfected patients⁶². The prevalence of HTLV infection in their cohort of HIV-infected individuals was 7.4%. The majority of coinfecting patients in the Beilke series were infected by HTLV-2 (56.5%), and no cases of myelopathy were described. Different from other reports, Posada-Vergara, et al. described some cases of myelopathy among HIV/HTLV-2-coinfected patients⁶³. In a prospective cohort, they identified four out of 37 HIV/HTLV-2-coinfected patients with myelopathy, while none of the 13 HTLV-2-monoinfected patients had neurologic abnormalities.

Peripheral neuropathy

Although there have been some controversies regarding the importance of peripheral nerve involvement in HTLV-infected individuals, peripheral neuropathy has been definitely described in association with this virus. Peripheral neuropathy associated with HTLV-1 is characterized by paresthesia, burning sensations, and abnormal superficial sensation distally in a stock and glove distribution and generally coupled with abolished ankle jerks. The greatest difficulty in these cases is to recognize some milder abnormalities in patients with HAM/TSP. A comprehensive history together with a meticulous neurologic examination looking for peripheral nerve dysfunction should lead to a precise diagnosis.

The reported frequency of peripheral neuropathy in HAM/TSP patients varies from negligible to 32%⁶⁴⁻⁶⁶. A few reports have described the occurrence of peripheral neuropathy in HTLV-1-infected individuals without HAM/TSP. In a recent clinical, electrophysiological, and anatomopathological study, peripheral neuropathy was identified in HTLV-1-infected individuals without HAM/TSP: 21 out of 335 patients (6.3%) had clinical and/or electrophysiological abnormalities suggestive of a polyneuropathy⁶⁷.

The pathogenesis of HTLV-1-related peripheral nerve diseases is presently unknown. Although less restrictive than the BBB, the blood-peripheral nerve barrier is also a limiting factor to the entrance of many substances and biological agents into the peripheral nerve microenvironment. The barrier appears to be located at the endoneurial capillaries. It is well known that the blood-peripheral barrier is absent at the dorsal root ganglia and in the terminal branches of sensory and motor nerves. The lack of a barrier at these sites may allow the entrance and retrograde transport of neurotoxins or inflammatory substances. This could explain the occurrence of isolated peripheral neuropathy even in the absence of HAM/TSP⁶⁷.

Regarding HIV infection, peripheral neuropathy is one of the most disabling and frequent complications occurring during this infection. Distal sensory polyneuropathy may be secondary to the HIV itself or may be due to the toxicity of some antiretrovirals. The clinical features of both conditions are identical, with pain and paresthesia being the main symptoms⁶⁸. Before HAART, distal sensory polyneuropathy was clinically diagnosed in about 89%⁶⁹ of patients. Nowadays, the majority of prospective studies estimate the incidence of peripheral neuropathy to be around 30%^{69,70}, with a

prevalence of 53%⁷¹. Noteworthy, histologic evidence of peripheral neuropathy in autopsy series is close to 100%⁶⁹.

A higher prevalence of peripheral neuropathy in HIV/HTLV-2 coinfection when compared with HIV mono-infection was reported by some groups, suggesting that HTLV-2 could be a predisposing cofactor to development of peripheral neuropathy in HIV-infected patients. Zehender, et al. studied 30 HIV/HTLV-2-coinfected patients for 28 months and reported a higher frequency of peripheral neuropathy in this group compared with HIV-monoinfected patients (OR: 3.3; $p < 0.009$)⁷². During the period of the study, one patient developed a myelopathy. More recently, in a large cohort followed for many years, Beilke, et al. verified that both HIV/HTLV-1 and HIV/HTLV-2-coinfected patients were more likely to present neurologic complications, including peripheral neuropathy, than HIV-monoinfected individuals⁷³. Harrison, et al. also described that HIV/HTLV-1-coinfected patients had a higher chance of developing peripheral neuropathy than HIV-monoinfected patients. However, this difference was weakened after adjustment for intravenous drug use history⁶¹.

Miscellaneous

An interesting speculation can be made regarding cognitive dysfunction in HIV/HTLV-coinfected patients. Infection with HIV can result in mild to severe cognitive deficits – the so called HIV dementia. Undoubtedly, HAART reduced dramatically the incidence of HIV dementia, but a considerable number of patients still exhibit cognitive decline nowadays. This can be explained by the effects of aging, since patients are surviving longer, and by neurodegeneration due to chronic presence of activated microglia. The pathogenesis of HIV dementia is out of the scope of this paper, but readers are referred to a recent review about this subject⁷⁰.

Cognitive dysfunction in HTLV-1 infection has been less studied. The interest for cognitive disturbances in HTLV-1 infection started after an increasing number of reports describing brain abnormalities in the magnetic resonance imaging of HAM/TSP patients^{74,75}. Since white matter lesions of HAM/TSP are in some aspects similar to those observed in patients with multiple sclerosis and in HIV-infected people, cognitive deficits in HAM/TSP patients may also occur. Most of the published papers on cognitive disturbances

in HAM/TSP describe psychomotor slowing, attention deficits, as well as visual and working memory deficits. However, a number of methodologic problems arise from many of these series. For example, extensive batteries for assessing cognitive dysfunction have been used in only three out of the nine published papers⁷⁶⁻⁷⁸, and in only one study a control group was used⁷⁸. The remaining papers are either case reports⁷⁹⁻⁸¹, studies on cognitive event-related potentials⁸², or epidemiologic surveys about the seroprevalence of HTLV-1 in demented patients^{83,84}. Our group demonstrated, through extensive neuropsychological assessment and with a negative control group, that HTLV-1 infection was associated with mild cognitive deficits, characterized by impairments in psychomotor speed, verbal fluency, verbal and visual memory, selective and alternate attention (mental flexibility), and visuoconstructive abilities⁸⁵. Both HAM/TSP patients and asymptomatic carriers had a worse performance in several tests when compared with the control group. The HIV/HTLV coinfection could be associated with a higher risk of neuropsychological dysfunction, but this hypothesis has not been formally assessed so far.

Although antiretroviral therapy has unquestionably changed the natural course of HIV disease, its role in HTLV infection is practically none. Two antiretroviral drugs have been tried in HAM/TSP. Zidovudine inhibited HTLV-1 reverse transcriptase both *in vitro* and in a rabbit infection model⁸⁶, but clinical trials in patients with HAM/TSP have shown conflicting results^{87,88}. Lamivudine was reported to reduce HTLV-1 proviral load in five patients, with clinical improvement in one patient with acute HAM/TSP⁸⁹. Recently, 16 patients were randomized to receive a combination of zidovudine and lamivudine or placebo⁹⁰. No significant changes were seen between the two arms regarding pain, bladder function, disability score, gait, proviral load, or markers of T-cell activation or proliferation. Failure to detect clinical improvement may reflect irreversible damage to the nerve tissue and lack of virologic effect may indicate inactivity of these nucleoside analogs against the HTLV-1 reverse transcriptase *in vivo*. Finally, the effects of HAART in coinfecting individuals have not been completely studied to date. The best evidences so far come from HIV/HTLV-2 coinfecting patients (see above) and show that antiretroviral therapy has an enhancing effect on proviral load⁵¹. Nevertheless, there is no evidence that this increase in proviral load is associated with neurologic diseases.

References

- Poiesz B, Ruscetti F, Gazdar A, Bunn P, Minna J, Gallo R. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci USA*. 1980;77:7415-9.
- Kalyanaraman V, Sarngadharan M, Robert-Guroff M, Miyoshi I, Golde D, Gallo R. A new subtype of HTLV-2 associated with a T-cell variant of hairy cell leukemia. *Science*. 1982;218:571-3.
- Osame M, Usuku K, Izumo S. HTLV-1 associated myelopathy, a new clinical entity. *Lancet*. 1986;1:1031-2.
- Araujo A, Silva M. The HTLV-1 neurological complex. *Lancet Neurol*. 2006;5:1068-76.
- Silva M, Harab R, Leite A, Schor D, Araujo A, Andrada-Serpa M. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. *Clin Infect Dis*. 2007;44:689-92.
- Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. *J Neurovirol*. 1998;4:586-93.
- Price R, Brew B, Sidtis J, Rosenblum M, Scheck A, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. *Science*. 1988;239:586-92.
- Silva M, Araujo A. Highly active antiretroviral therapy access and neurological complications of HIV infection: impact versus resources in Brazil. *J Neurovirol*. 2005;11(Suppl 3):11-5.
- Johnson J, Franchini G. Retroviral proteins that target the major histocompatibility complex class I. *Virus Res*. 2002;88:119-27.
- Bindhu M, Nair A, Lairmore M. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. *Front Biosci*. 2004;9:2556-76.
- Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. *J Clin Virol*. 2005;34:233-44.
- Fan N, Gavalchin J, Paul B, Wells K, Lane M, Poiesz B. Infection of peripheral blood mononuclear cells and cell lines by cell-free HTLV-1. *J Clin Microbiol*. 1992;30:905-10.
- Roy U, Simpson S, Mondal D, Eloby-Childress S, Winsor E, Beilke M. Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 *in vitro*. *J Med Virol*. 2008;80:494-500.
- Kubota S, Furuta R, Hatanaka M, Pomerantz R. Modulation of HTLV-1 gene expression by HIV-1 Rev through an alternative RRE-independent pathway mediated by the RU5 portion of the 5'-LTR. *Biochem Biophys Res Commun*. 1998;243:79-85.
- Beilke M, Japa S, Vinson D. HTLV-1 and HTLV-2 virus expression increase with HIV-1 coinfection. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;17:391-7.
- De Rossi A, Saggioro D, Calabro M, Cenzato R, Chieco-Bianchi L. Reciprocal activation of human T-lymphotropic viruses in HTLV-1-transformed cells superinfected with HIV-1. *J Acquir Immune Defic Syndr*. 1991;4:380-5.
- Olah I, Fukumori L, Montanheiro P, et al. Patterns of *in vitro* lymphoproliferative responses among HTLV-1-infected subjects: upregulation by HTLV-1 during HIV-1 coinfection. *Scand J Immunol*. 2007;65:577-80.
- Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient HIV replication in mobile lymphocytes. *J Virol*. 2007;81:1000-12.
- Jolly C, Kashefi K, Hollinshead M, Sattentau Q. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. *J Exp Med*. 2004;199:283-93.
- Jolly C, Sattentau Q. Retroviral spread by induction of virologic synapses. *Traffic*. 2004;5:643-50.
- Stebbing J, Gazzard B, Douek D. Where does HIV live? *N Engl J Med*. 2004;350:1872-80.
- Kazanji M, Ureta-Vidal A, Ozden S, et al. Lymphoid organs as a major reservoir for HTLV-1 in experimentally infected squirrel monkeys (*Saimiri sciureus*): provirus expression, persistence, and humoral and cellular immune responses. *J Virol*. 2000;74:4860-7.
- Takenouchi N, Matsuoka E, Moritoyo T, et al. Molecular pathologic analysis of the tonsil in HTLV-1-infected individuals. *J Acquir Immune Defic Syndr*. 1999;22:200-7.
- Bangham C. The immune control and cell-to-cell spread of HTLV-1. *J Gen Virol*. 2003;84:3177-89.
- Igakura T, Stinchcombe J, Goon P, et al. Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. *Science*. 2003;299:1713-6.
- Sun J, Barbeau B, Tremblay M. HIV-1-mediated syncytium formation promotes cell-to-cell transfer of Tax protein and HTLV-1 gene expression. *Virus Res*. 2006;118:120-9.
- Casoli C, Vicenzi E, Cimarelli A, et al. HTLV-2 downregulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfecting individuals through expression of MIP-1alpha. *Blood*. 2000;95:2760-9.

28. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. *Science*. 1993;261:1179-81.
29. Berger E, Doms R, Fenyo E, et al. A new classification for HIV-1. *Nature*. 1998;391:240.
30. Connor R, Sheridan K, Ceradini D, Choe S, Landau N. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. *J Exp Med*. 1997;185:621-8.
31. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. *Nat Med*. 1997;3:1259-65.
32. Biddison W, Kubota R, Kawanishi T, et al. Human T cell leukemia virus type 1 (HTLV-1)-specific CD8+ CTL clones from patients with HTLV-1-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. *J Immunol*. 1997;159:2018-25.
33. Moriuchi H, Moriuchi M, Fauci A. Factors secreted by HTLV-1-infected cells can enhance or inhibit replication of HIV-1 in HTLV-1-uninfected cells: implications for in vivo coinfection with HTLV-1 and HIV-1. *J Exp Med*. 1998;187:1689-97.
34. Nyland S, Specter S, Ugen K. Morphine effects on HTLV-1 infection in the presence or absence of concurrent HIV-1 infection. *DNA Cell Biol*. 1999;18:285-91.
35. Szabo J, Beck Z, Csoman E, et al. Differential patterns of interaction between HIV-1 and HTLV-I in monocyte-derived macrophages cultured in vitro: implications for in vivo coinfection with HIV-1 and HTLV-I. *AIDS Res Hum Retroviruses*. 1999;15:1653-66.
36. Bassani S, Lopez M, Toro C, et al. Influence of HTLV-2 coinfection on virologic and immunological parameters in HIV type 1-infected patients. *Clin Infect Dis*. 2007;44:105-10.
37. Casseb J, Posada-Vergara M, Montanheiro P, et al. T CD4+ cells count among patients coinfecting with HIV-1 and HTLV-1: high prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). *Rev Inst Med Trop Sao Paulo*. 2007;49:231-3.
38. Schechter M, Moulton L, Harrison L. HIV viral load and CD4+ lymphocyte counts in subjects coinfecting with HTLV-1 and HIV-1. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1997;15:308-11.
39. Bovalenta C, Pilotti E, Mauri M, et al. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factor. *Blood*. 2002;99:224-31.
40. Afonso P, Ozden S, Cumont M, et al. Alteration of blood-brain barrier integrity by retroviral infection. *PLoS Pathog*. 2008;4:e1000205.
41. Lehky T, Fox C, Koenig S, et al. Detection of HTLV-1 tax RNA in the central nervous system of HTLV-1-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. *Ann Neurol*. 1995;37:167-75.
42. Mor-Vaknin N, Turgeman H, Torgeman A, Wolfson M, Huleihel M, Aboud M. Rapid syncytium formation between HTLV-1-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-1 associated myelopathy. *Cell Biol Int*. 1998;22:95-103.
43. Barcia C, Sanderson N, Barrett R, et al. T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. *PLoS ONE*. 2008;3:e2977.
44. Wang H, Sun J, Goldstein H. HIV-1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. *J Virol*. 2008;82:7591-600.
45. Shieh J, Martin J, Baltuch G, Malim M, Gonzalez-Scarano F. Determinants of syncytium formation in microglia by HIV-1: role of the V1/V2 domains. *J Virol*. 2000;74:693-701.
46. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. *Curr HIV Res*. 2008;6:388-400.
47. Levin M, Rosenblum M, Fox C, Jacobson S. Localization of retrovirus in the central nervous system of a patient coinfecting with HTLV-1 and HIV with HAM/TSP and HIV-associated dementia. *J Neurovirol*. 2001;7:61-5.
48. Cesaire R, Dehee A, Lezin A, et al. Quantification of HTLV type 1 and HIV type 1 DNA load in coinfecting patients: HIV type 1 infection does not alter HTLV type 1 proviral amount in the peripheral blood compartment. *AIDS Res Hum Retroviruses*. 2001;17:799-805.
49. Woods T, Graber J, Hershow R, Khabbaz R, Kaplan J, Heneine W. Investigation of proviral load in individuals infected with HTLV-2. *AIDS Res Hum Retroviruses*. 1995;11:1235-9.
50. Machuca A, Soriano V. In vivo fluctuation of HTLV-1 and HTLV-2 proviral load in patients receiving antiretroviral drugs. *J Acquir Immune Defic Syndr*. 2000;24:189-93.
51. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. *J Acquir Immune Defic Syndr*. 2006;41:100-6.
52. Orland J, Engstrom J, Frider J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. *Neurology*. 2003;61:1588-94.
53. Poesz B, Dube D, Dube S, et al. HTLV-2-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. *N Engl J Med*. 2000;342:930-6.
54. Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-2 infection in injection-drug users. *Neurology*. 1996;46:1556-60.
55. Zehender G, Colasante C, De Maddalena C, et al. High prevalence of HTLV-1 in immigrant male-to-female transsexual sex workers with HIV-1 infection. *J Med Virol*. 2004;74:207-15.
56. Zehender G, Colasante C, Santambrogio S, et al. Increased risk of developing peripheral neuropathy in patients coinfecting with HIV-1 and HTLV-2. *J Acquir Immune Defic Syndr*. 2002;31:440-7.
57. Araujo A, Leite A, Dutra S, Andrade-Serpa M. Progression of neurological disability in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). *J Neurol Sci*. 1995;127:147-51.
58. Takenouchi N, Yamano Y, Usuku K, Osame S, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. *J Neurovirol*. 2003;9:29-35.
59. Araujo A, Hall W. Human T-lymphotropic virus type II and neurological disease. *Ann Neurol*. 2004;56:10-9.
60. Dal Pan G, Glass J, McArthur J. Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. *Neurology*. 1994;44:2159-64.
61. Harrison L, Vaz B, Taveira D, et al. Myelopathy among Brazilians coinfecting with HTLV-1 and HIV. *Neurology*. 1997;48:13-8.
62. Beilke M, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfecting patients. *Clin Infect Dis*. 2005;41:e57-63.
63. Posada-Vergara M, Montanheiro P, Fukumori L, et al. Clinical and epidemiological aspects of HTLV-2 infection in Sao Paulo, Brazil: presence of tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) simile diagnosis in HIV-1-co-infected subjects. *Rev Inst Med Trop Sao Paulo*. 2006;48:207-10.
64. Montgomery R, Cruickshank J, Robertson W, McMenemey W. Clinical and pathological observations on Jamaican neuropathy. A report on 206 cases. *Brain*. 1964;87:425-62.
65. Barkhaus P, Morgan O. Jamaican neuropathy: an electrophysiological study. *Muscle Nerve*. 1988;11:380-5.
66. Roman G, Roman L. Tropical spastic paraparesis. A clinical study of 50 patients from Tumaco (Colombia) and review of the worldwide features of the syndrome. *J Neurol Sci*. 1988;87:121-38.
67. Leite A, Silva M, Alamy A, et al. Peripheral neuropathy in HTLV-1 infected individuals without tropical spastic paraparesis/HTLV-1-associated myelopathy. *J Neurol*. 2004;251:877-81.
68. Gonzalez-Duarte A, Robinson-Papp J, Simpson D. Diagnosis and management of HIV-associated neuropathy. *Neurol Clin*. 2008;26:821-32. x.
69. Hoke A, Cornblath D. Peripheral neuropathies in HIV infection. *Suppl Clin Neurophysiol*. 2004;57:195-210.
70. McArthur J, Brew B, Nath A. Neurological complications of HIV infection. *Lancet Neurol*. 2005;4:543-55.
71. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of HAART: the Manhattan HIV Brain Bank. *Arch Neurol*. 2004;61:546-51.
72. Zehender G, De Maddalena C, Osio M, et al. High prevalence of HTLV-2 infection in patients affected by HIV-associated predominantly sensory polyneuropathy. *J Infect Dis*. 1995;172:1595-8.
73. Beilke M, Theall K, O'Brien M, et al. Clinical outcomes and disease progression among patients coinfecting with HIV and HTLV types 1 and 2. *Clin Infect Dis*. 2004;39:256-63.
74. Tournier-Lasserre E, Gout O, Gessain A, et al. HTLV-1, brain abnormalities on magnetic resonance imaging, and relation with multiple sclerosis. *Lancet*. 1987;2:49-50.
75. Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K. Leukoencephalopathy in HTLV-1-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. *J Neurol Sci*. 1991;106:41-9.
76. Cartier L, Gormaz A, Araya F, Castillo J. Cognitive function in progressive spastic paraparesis associated to HTLV-1: A preliminary study. *Rev Chil Neuro-Psiquiat*. 1992;30:241-6.
77. Cartier L, Gormaz A. [Subcortical dementia in HTLV-I tropical spastic paraparesis. Study of 43 cases]. *Rev Med Chil*. 1999;127:444-50.
78. Castillo J, Camposano S, Cartier L, Gormaz A, Quevedo F. Event related potentials in progressive spastic HTLV-1 positive and negative paraparesis. *Rev Chil Neuro-Psiquiat*. 1995;33:45-50.
79. Cartier L, Gormaz A, Kleinstaub K, Ramirez E, Galeno H. [New form of subcortical dementia: encephalopathy due to infection with HTLV-1. Clinical case]. *Rev Med Chil*. 1997;125:209-13.
80. Cartier L, Araya F, Castillo J, et al. Subacute encephalomyelopathy associated with HTLV-I: pseudobulbar paralysis and mental deterioration. *Neurology*. 1990;40(Suppl 1):238.

81. Lycke J, Svennerholm B, Svenningsson A, Horal P, Nordqvist-Brandt E, Andersen O. Possible association of HTLV-1 infection and dementia. *Acta Neurol Scand.* 1993;88:199-203.
82. Fukushima T, Ikeda T, Uyama E, Uchino M, Okabe H, Ando M. Cognitive event-related potentials and brain magnetic resonance imaging in HTLV-1 associated myelopathy (HAM). *J Neurol Sci.* 1994;126:30-9.
83. Kira J, Hamada T, Kawano Y, Okayama M, Yamasaki K. An association of HTLV-1 infection with vascular dementia. *Acta Neurol Scand.* 1997;96:305-9.
84. Sulkava R, Korpela J, Erkinjuntti T. No antibodies to HTLV-1 and HIV in patients with dementia in Finland. *Acta Neurol Scand.* 1987;76:155-6.
85. Silva M, Mattos P, Alfano A, Araujo A. Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls. *J Neurol Neurosurg Psychiatry.* 2003;74:1085-9.
86. Isono T, Ogawa K, Seto A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. *Leuk Res.* 1990;14:841-7.
87. Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-1. *J Neurol.* 1991;238:108-9.
88. Sheremata W, Benedict D, Squillacote D, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. *Neurology.* 1993;43:2125-9.
89. Taylor G, Hall S, Navarrete S, et al. Effect of lamivudine on HTLV-1 DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. *J Virol.* 1999;73:10289-95.
90. Taylor G, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in HTLV-1-associated myelopathy: a randomised trial. *Retrovirology.* 2006;3:63.